慢性支气管感染与慢阻肺患者心血管事件:一项长期观察性研究
该研究对201例GOLD II-IV级慢阻肺患者进行为期84个月的前瞻性队列事后分析,每3-6个月随访一次。结果显示,慢性支气管感染(CBI)与持续性全身炎症及心血管事件发生率显著升高相关(HR 3.88;95%CI 1.83-8.22),且以冠脉事件为主;该关联在铜绿假单胞菌(PA)所致CBI患者中尤为显著。
要点
- CBI与慢阻肺患者心血管事件风险升高独立相关。
- PA所致的CBI与全身炎症及心血管事件关联尤为显著。
- 治疗CBI能否降低全身炎症与心血管事件尚待干预性研究验证。
核心结论
- CBI尤其由PA引起的CBI,与持续性且增强的全身炎症及更高的心血管事件(尤其是冠脉事件)发生率相关。
- 研究者提出,治疗CBI可能降低慢阻肺患者全身炎症与心血管事件,值得开展前瞻性干预研究。
研究设计与样本
- 研究为对前瞻性收集的201例GOLD II-IV级慢阻肺患者队列的事后分析,随访84个月,每3-6个月随访一次。
- CBI定义为1年内至少3次阳性致病微生物痰培养,且各次间隔至少3个月;全身炎症以循环C反应蛋白和纤维蛋白原水平评估。
- 致命与非致命心血管事件(含冠脉事件、脑血管事件及心律失常)被前瞻性记录,分析时分别统计并合并为复合变量。
主要发现
- CBI与持续性全身炎症及显著更高的心血管事件发生率相关(HR:3.88;95%CI:1.83-8.22),主要为冠脉来源。
- 上述关联独立于年龄、急性加重次数与严重程度、合并症、其他心血管危险因素、肺功能、BMI、吸烟状态及治疗。
- 该关联在由铜绿假单胞菌(PA)所致CBI的患者中尤为显著。
临床怎么用
- 对慢阻肺患者应关注慢性支气管感染状态,尤其PA感染,作为心血管风险分层与随访的参考信息。
- 原文提示治疗CBI或可降低全身炎症与心血管事件,但尚需前瞻性干预研究验证,暂不作为临床推荐。
局限性
- 本研究为单队列事后分析,样本量201例,结论需前瞻性干预研究进一步验证。
- 原文摘要未报告研究的具体局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Cardiovascular (CV) diseases are frequent in patients with chronic obstructive pulmonary disease (COPD). Likewise, chronic bronchial infection (CBI) is also frequent in COPD and it is associated with systemic inflammation, a well-known CV risk factor. The objective of this study was to investigate the relationship between CBI, systemic inflammation and incident CV events. METHODS: A post hoc analysis of prospectively collected cohort of 201 COPD patients [Global Initiative for Chronic Obstructive Lung Disease (GOLD) II-IV] followed up every 3-6 months for 84 months was conducted. CBI was defined as ≥3 positive pathogenic microorganisms sputum cultures over 1 year, separated by ≥3 months. Systemic inflammation was assessed by circulating levels of C-reactive protein and fibrinogen. Fatal and non-fatal CV events, including coronary and cerebrovascular events as well as arrhythmia episodes, were prospectively recorded. For analysis, they were analysed separately and combined in a composite variable. RESULTS: As hypothesized, CBI was associated with persistent systemic inflammation and a significantly higher incidence of CV events (HR: 3.88; 95% CI: 1.83-8.22), mainly of coronary origin independent of age, number and severity of exacerbations, comorbidities, other CV risk factors, lung function, BMI, smoking status and treatments. These associations were particularly significant in patients with CBI by Pseudomonas aeruginosa (PA). CONCLUSION: CBI, particularly by PA, is associated with sustained and enhanced systemic inflammation and a higher incidence of CV events (especially coronary events). The possibility that treating CBI may decrease systemic inflammation and CV events in COPD deserves prospective, interventional studies.
引用
- Martinez-Garcia MÁ, Faner R, Oscullo G, et al. Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A long-term observational study. Respirology. 2021. PMID: 34002922. doi:10.1111/resp.14086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。